Clinical trialPhase 2Recruiting
Namodenoson Treatment of Advanced Pancreatic Cancer
CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 10 November 2024
- Expected end
- 15 December 2026
- Enrollment
- 20 participants
- Sites
- 1
- Primary outcomes
- Adverse Events; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline
- Sponsor
- Industry
- Results posted
- No
- Last update
- 31 January 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try